1. Clinical impact of HLA class I expression in rectal cancer

   • Frank M. Speetjens
   • Elza C. de Bruin
   • Peter J. K. Kuppen

   Original Article Open access 15 September 2007 Pages: 601 - 609

   

2. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2

   • Tsukasa Nabekura
   • Toshiro Nagasawa
   • Masafumi Onodera

   Original Article 05 September 2007 Pages: 611 - 622

   

3. Adoptive transfer of T_reg depleted autologous T cells in advanced renal cell carcinoma

   • Fiona C. Thistlethwaite
   • Eyad Elkord
   • Robert E. Hawkins

   Original Article 27 September 2007 Pages: 623 - 634

   

4. Migration deficit in monocyte-macrophages in human ovarian cancer

   • Ralph S. Freedman
   • Qing Ma
   • Francesco M. Marincola

   Original Article 10 October 2007 Pages: 635 - 645

   

5. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

   • A. Nazmul H. Khan
   • Christopher J. Gregorie
   • Thomas B. Tomasi

   Original Article 28 November 2007 Pages: 647 - 654

   

6. Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model

   • Melissa A. Barber
   • Tong Zhang
   • Charles L. Sentman

   Original Article 22 September 2007 Pages: 655 - 662

   

7. Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction

   • Hovav Nechushtan
   • Dien Pham
   • Joseph D. Rosenblatt

   Original Article 19 October 2007 Pages: 663 - 675

   

8. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients

   • Hui Wang
   • Chuanping Cao
   • Dianwen Ju

   Original Article 13 October 2007 Pages: 677 - 684

   

9. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

   • Selma Ugurel
   • David Schrama
   • Jürgen C. Becker

   Original Article 02 October 2007 Pages: 685 - 691

   

10. MYCN as a target for cancer immunotherapy

    • Nourredine Himoudi
    • Mengyong Yan
    • John Anderson

    Original Article 15 November 2007 Pages: 693 - 700

    

11. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors

    • Paula Chiarella
    • Marisa Vulcano
    • Raúl A. Ruggiero

    Original Article 26 October 2007 Pages: 701 - 718

    

12. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines

    • Rosa Méndez
    • Teresa Rodríguez
    • Federico Garrido

    Original Article 13 October 2007 Pages: 719 - 729

    

13. Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma

    • Anna De Geer
    • Lena-Maria Carlson
    • Jelena Levitskaya

    Original Article 26 October 2007 Pages: 731 - 743

    

14. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes

    • Pierre Larrieu
    • Virginie Renaud
    • Jean-François Fonteneau

    Original Article 21 December 2007 Pages: 745 - 752

    

15. Acknowledgement

    Acknowledgement to Reviewers Open access 14 February 2008 Pages: 753 - 757